HAE•November 18, 2026 at 11:15 AM UTCHealth Care Equipment & Services

Haemonetics Expands VASCADE MVP XL into Europe with CE Mark

Read source article

What happened

Haemonetics announced CE Mark certification for its VASCADE MVP XL venous vascular closure system, enabling commercialization in the European Union and other CE-recognizing geographies. The first European procedures with the system were performed in October in Germany, Italy, and the UK, signaling early clinical adoption. This regulatory milestone directly supports Haemonetics' strategy to grow its Hospital segment, which has been the primary source of resilience amid Plasma headwinds. The VASCADE MVP family, including the XL variant, is positioned to capture demand from the rapidly expanding electrophysiology and pulsed-field ablation (PFA) market, where multi-access venous closure is increasingly required. While the certification strengthens Haemonetics' international competitive positioning, the company still faces a near-term revenue step-down from the CSL Plasma disposables transition in North America.

Implication

For investors, the CE Mark for VASCADE MVP XL is a tangible step in expanding Haemonetics' Hospital franchise beyond the U.S., where it already holds leading positions. It should support sustained mid-single-digit to high-single-digit growth in Hospital as European electrophysiology and PFA procedures increase. However, this news does not resolve the fiscal 2026 revenue step-down from the CSL Plasma transition, which remains the primary overhang on consolidated growth and margins. The certification also provides a clearer path for international revenue diversification, potentially reducing reliance on North American Plasma customers over time. Overall, this is a modest positive that reinforces the quality of the Hospital portfolio but does not yet warrant a change in the neutral stance until Plasma stabilizes.

Thesis delta

The CE mark for VASCADE MVP XL adds a new catalyst for Hospital segment international growth, but it does not change the fundamental thesis. Haemonetics remains a company with a strong Hospital franchise offset by near-term Plasma headwinds. The investment case still hinges on whether Hospital outperformance can offset the CSL decline and eventually lead to a re-rating.

Confidence

High